Abstract
Plasma renin activity (PRA) levels have been used to define two categories of essential hypertensive patients differing for the basic pathophysiological mechanisms sustaining high blood pressure and for the responsiveness to different antihypertensive agents. In particular, patients with low-renin hypertension should respond better to antisodium-volume drugs and patients with normal- to high-renin hypertension should respond better to renin angiotensin aldosterone system-targeted drugs. Although the experimental verification of this treatment algorithm in both retrospective and prospective analyses of several clinical trials has led to mixed results, the recommendations from the British Hypertension Society can be interpreted in the light of this approach by substituting the direct determination of PRA with the use of demographic parameters (such as race and age), which have been demonstrated to be strictly correlated to PRA levels. Furthermore, the use of PRA screening has also been advocated in cases of resistant hypertension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991 Apr; 324(16): 1098–104
Laragh JH. Abstract, closing summary, and table of contents for Laragh’s 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. Am J Hypertens 2001 Dec; 14(12): 1173–7
Mulatero P, Milan A, Williams TA, et al. Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 2006 Jan; 4(1): 75–91
DiBona GF, Sawin LL. Renal tubular site of action of felodipine. J Pharmacol Exp Ther 1984 Feb; 228(2): 420–4
Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and pro-inflammatory mediators in cardiovascular disease. Am J Cardiol 2006 Jul; 98(1): 121–8
Del Colle S, Morello F, Rabbia F, et al. Antihypertensive drugs and the sympathetic nervous system. J Cardiovasc Pharmacol 2007 Nov; 50(5): 487–96
Blumenfeld JD, Laragh JH. Renin system analysis: a rational approach for the diagnosis and treatment of the individual patient. Am J Hypertens 1998 Jul; 11(7): 894–6
Wing LM, Reid CM, Ryan P, et al., for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003 Feb; 348(7): 583–92
Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003 May; 16(5): 407–15
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blockers vs diuretic: the Anti-hypertensive and Lipid Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002 Dec; 288 (23): 2981–97
Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005 Sep; 150(3): 426–33
Mahmud A, Mahgoub M, Hall M, et al. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Am J Hypertens 2005 Dec; 18(12): 1631–5
Rosenthal J, Jaeger H, Arlart I. Effect of prazosin on blood pressure and plasma renin activity in man. Clin Sci Mol Med Suppl 1978 Dec; 4: 337s–9s
Flack JM, Oparil S, Pratt JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003 Apr; 41(7): 1148–55
Hood SJ, Taylor KP, Ashby MJ, et al. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007 Jul; 116(3): 268–75
Williams B, Poulter NR, Brown MJ, et al. BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004 Mar; 328(7440): 634–40
Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006 Jun; 81(6): 796–806
Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999 Jun; 353(9169): 2008–113
Preston RA, Materson BJ, Reda DJ, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998 Oct; 280(13): 1168–72
Chapman AB, Schwartz GL, Boerwinkle E, et al. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 2002 Mar; 61(3): 1047–55
Sareli P, Radevski IV, Valtchanova ZP, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med 2001 Apr; 161(7): 965–71
Alderman MH, Cohen HW, Sealey JE, et al. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004 Jan; 17(1): 1–7
Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep 2002 Jun; 4(3): 221–8
Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001 Mar; 19(3): 363–6
Ouzan J, Pérault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002 Apr; 15(4): 333–9
Nishizaka MK, Calhoun DA. The role of aldosterone antagonists in the management of resistant hypertension. Curr Hypertens Rep 2005 Oct; 7(5): 343–7
Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004 Nov; 22(11): 2217–26
Naudzhunas A, Bagdonas G, Yankauskene L, et al. Use of spironolactone and indapamide in the treatment of low-renin arterial hypertension. Ter Ark 2006; 78(2): 61–4
Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003 Nov; 16(11): 925–30
Acknowledgements
No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verhovez, A., Mulatero, P., Bertello, C. et al. Is Renin-Based Treatment a Reasonable Strategy to Treat Essential Hypertension?. High Blood Press Cardiovasc Prev 15, 121–125 (2008). https://doi.org/10.2165/0151642-200815030-00005
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2165/0151642-200815030-00005